iSpecimen's $4.5 million AI deal hinges on a stockholder vote and gated milestone payments
A $4.5 million Asset Purchase Agreement, filed with the SEC on September 4, puts two disease-intelligence AI products in focus for $ISPC (iSpecimen Inc., Nasdaq). The deal targets assets from Foldlab AI Ltd., a British…
Key takeaways
- iSpecimen Inc. ($ISPC, Nasdaq) filed a $4.5 million Asset Purchase Agreement with the SEC on September 4 to acquire two disease-intelligence AI products from Foldlab AI Ltd. of British Columbia.
- The acquired assets are a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model.
- The $4.5 million consists of $2 million in cash and $2.5 million in iSpecimen common stock, with $750,000 cash due at closing and two $625,000 milestone payments earned only on successful delivery, testing, and acceptance of each AI product.
- The transaction cannot close without iSpecimen stockholder approval of both the deal and the share issuance under Nasdaq Listing Rule 5635(a).
- iSpecimen may terminate if closing conditions are not met within 120 days of September 4, with an option to extend up to 60 additional days, and termination triggers no portion of the purchase price.
A $4.5 million Asset Purchase Agreement, filed with the SEC on September 4, puts two disease-intelligence AI products in focus for $ISPC (iSpecimen Inc., Nasdaq). The deal targets assets from Foldlab AI Ltd., a British Columbia company, and covers a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model. Stockholder approval is the gate that must open before the transaction can close.
Deal mechanics and gated cash
The $4.5 million breaks into $2 million in cash and $2.5 million in iSpecimen common stock. Of the cash, $750,000 is due at closing by wire. The remaining $1.25 million splits into two milestone payments of $625,000 each, payable only on successful delivery, testing, and acceptance of each AI product. The Agreement is explicit that no milestone payment is earned for partial performance, a failed test, or any unresolved material defect.
The share component is sized using the ten-day volume-weighted average price ending the trading day before closing, rounded down to the nearest whole share. Those shares go into a five-year escrow with no leak-out. Foldlab and any subsequent holder cannot sell, transfer, pledge, hedge, short, or lend the escrowed shares during that term, and all dividends and split shares stay locked under the same conditions. An irrevocable proxy attached to those shares lets iSpecimen vote them on matters covering the transaction itself, including issuance, listing, and any change of control.
Closing conditions and the outside date
Closing requires the Seller's representations to hold, Foldlab to deliver a completed disclosure schedule, Nasdaq to confirm the listing of the new shares, and iSpecimen's stockholders to approve the transaction and the share issuance under Nasdaq Listing Rule 5635(a). Regulatory consents and an absence of any material adverse effect on the transferred assets are also required.
If those conditions are not satisfied within 120 days of September 4, iSpecimen may terminate. The Company holds an option to extend that window by up to 60 additional days. Termination does not trigger any portion of the purchase price.
Indemnification runs from Foldlab to iSpecimen for breaches, pre-closing liabilities, intellectual property infringement claims, data and privacy failures, fraud, and willful misconduct. General representation claims carry a $25,000 deductible basket and a $100,000 aggregate cap; claims tied to fraud, intentional misrepresentation, or willful misconduct fall outside both limits.
The proxy filing is the next document to watch.